Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
CEO
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the company’s Chief Executive Officer,
“Vistagen is holding a series of meetings with influential leaders across the country to discuss the current challenges in our nation’s mental health crisis and advance needed solutions,” said
The impact of the COVID-19 pandemic on mental health and mental health systems has been profound and will likely continue for many years to come. The webinar will address how
The webinar, “Addressing Stigmas and Solutions to Mental Health Challenges,” is taking place on
-
Kana Enomoto – Director ofBrain Health ,McKinsey Health Institute -
Malisa Aksentijevic – Founder and CEO,WEVO Group -
Dr.
Zabina Bhasin – Founder, In KidZ
Registration information can be found here.
The webinar is the third Concordia event focused on prioritizing mental health and outlining strategies and recommendations to address this growing crisis. It quickly follows last month’s successful 2022 Concordia Summit, where Singh joined Founder of the MindUP™ |
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which are odorless and tasteless investigational neuroactive steroids designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.Vistagen.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "project," "outlook," "strategy," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "strive," "goal," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. These risks are fully discussed in the section entitled "Risk Factors" in the Company’s most recent Annual Report on Form 10-K for the fiscal year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005459/en/
Investors:
Vice President, Investor Relations
(650) 577-3617
mflather@vistagen.com
Media:
SKDK
nhitchings@skdknick.com
Source: Vistagen